Global Economic Growth and Investor Sentiment: Weakening global growth, influenced by factors like the Middle East conflict and IMF forecast downgrades, could reduce investor appetite for riskier, high-growth biopharmaceutical stocks such as BBOT, potentially affecting its valuation and access to capital.

Inflation and R&D Costs: Rising inflation, potentially indicated by higher oil prices, could lead to increased operational and research & development costs for BridgeBio Oncology Therapeutics, impacting the expenses associated with clinical trials and drug development.

Biotechnology Sector Funding Environment: The overall investment climate for the biotechnology sector, which is sensitive to general market risk sentiment, interest rate changes, and the regulatory landscape for drug approvals (e.g., FDA processes), directly influences BBOT's ability to secure funding and advance its pipeline.